COLTHARP DOUGLAS E sold $2.4M of EHC

COLTHARP DOUGLAS E (EVP & Chief Financial Officer) sold 18,869 shares of Encompass Health Corp (EHC) at $125.38 ($2.37M total) on 2026-08-10.

Original reporting
SEC EDGAR · COLTHARP DOUGLAS E
Published Aug 11, 2026, 6:47 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 11, 2026, 6:49 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$EHC
Neutral
medium confidence
Mentioned
$EHC
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EHCNeutralLow
01

Why it matters

Insider selling can slightly pressure sentiment, but without accompanying operational or financial updates, it is unlikely to drive a sustained repricing.

02

Market read

Traders may note the insider sale for sentiment monitoring, but there is no new guidance, contract, or regulatory development.

03

What to watch

The article does not state whether the sale was part of a 10b5-1 plan (it says no), but it also provides no context on motivations or future trading intentions.

Relevance 6/10Novelty 3/10Timing: today’s SEC Form 4 filing

Background

The article is an SEC Form 4 insider transaction disclosure for Encompass Health Corp.

Company-level read

Ticker impact

$EHCNeutralMedium confidence
Context

Encompass Health CFO Coltharp Douglas sold 18,869 shares in an open-market transaction worth about $2.37M, per Form 4 filed today.

Expected impact

Likely limited, short-lived impact unless paired with other negative news.

Evidence & confidence

The filing is a routine Form 4 open-market sale with no 10b5-1 plan stated; insider selling can be interpreted both ways, and the article provides no earnings, guidance, or operational catalyst.

Market effects

Minimal, as the disclosure is company-specific insider selling without sector-wide signal.

None indicated.

None indicated.

Counterpoint

The sale may be unrelated to fundamentals (taxes, diversification, planned liquidity needs), so it should not be over-weighted.

Key entities

  • Encompass Health Corp

    Subject of the Form 4 insider transaction disclosure.

  • COLTHARP DOUGLAS E

    EVP and Chief Financial Officer who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$EHCMed

Raymond James raises Encompass Health stock price target on strong results

Raymond James raised its price target for Encompass Health (EHC) to $155 from $150, citing strong Q3 results and raised guidance. The company beat EBITDA expectations for the 16th straight quarter, driven by acuity and cost control. EHC shares are near their 52-week high, up 32% in six months. Analysts like UBS, KeyBanc, and Truist also raised their price targets, noting strong EBITDA performance and positive 2027 outlook.

$EHCMedAI 8/10

KeyBanc raises Encompass Health stock price target on strong earnings

KeyBanc raised its price target for Encompass Health (NYSE:EHC) to $150 from $147, citing strong Q3 results. Core EBITDA beat estimates by 10% with 23% YoY growth, driven by acuity improvements and expense management. The company reported $1.52B EBITDA over the last 12 months. Same-store volumes grew 3.0%, with expectations of further improvement. Management is optimistic about 2027 and RCD expansion. The stock has returned 32% over six months, trading near its 52-week high of $133.75.

$EHCHigh

Truist raises Encompass Health stock price target on strong results

Truist Securities raised its price target on Encompass Health (NYSE:EHC) to $156 from $150, citing strong Q3 results. The company reported adjusted EBITDA of $1.52B and a 32% stock return over six months. Encompass Health raised its guidance despite headwinds and is expanding capacity. The stock trades near its 52-week high of $133.75, with a financial health score of 3.35 out of 5.